- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
New treatment options for aggressive lymphomas
23 December 2019
found drug combinations including Mcl-1 inhibitors
could be effective in treating mantle cell lymphoma.
Combining a new anti-cancer drug targeting Mcl-1 with current cancer therapies could be an effective strategy for treating aggressive lymphomas, new research has found.
Cancer researchers from the Walter and Eliza Hall Institute treated patient-derived mantle cell lymphomas with an Mcl-1 inhibitor, alone or together with approved targeted cancer drugs ibrutinib or venetoclax. The results showed that the treatments, particularly the combination therapy, could kill the cancer cells in tissue culture and preclinical models.
The study, led by Dr Michael Dengler and Professor Jerry Adams in collaboration with Institute colleagues, was published in the journal Oncogene.
At a glance
- Mantle cell lymphomas are aggressive blood cancers that remain incurable with standard therapies.
- Our researchers have shown that Mcl-1 inhibitors, alone or in combination with approved targeted cancer drugs, could be an effective new therapy option for mantle cell lymphomas.
- Targeting Bcl-2 family members, which include Bcl-2 itself and Mcl-1, has proven to be a very effective strategy for treating cancers.
An aggressive disease
Dr Dengler said mantle cell lymphoma was an uncommon but aggressive type of lymphoma with a poor prognosis.
“People with mantle cell lymphoma typically respond well to therapy at first, but then relapse and exhaust treatment options pretty quickly,” Dr Dengler said.
“Mantle cell lymphoma is currently incurable with standard chemotherapy, so new treatments are urgently needed for patients with this aggressive disease.”
In the new study, the research team used mantle cell lymphoma tissue donated by patients to trial anti-cancer treatment combinations in the laboratory.
“The results were very promising. The Mcl-1 inhibitor could effectively kill not only the cells in our mantle cell lymphoma cell lines, but also in tumours freshly isolated from patients and in preclinical models. Combining the Mcl-1 inhibitor with either the approved therapeutics venetoclax or ibrutinib further exacerbated the killing," he said.
“Our results suggest that treatment combinations using Mcl-1 inhibitors and other targeted cancer therapeutics could offer clinicians better options for treating mantle cell lymphoma patients and should be evaluated in clinical trials.”
Signalling sabotage
Mantle cell lymphoma grows in lymph nodes, and the cancer cells receive signals from the tumour microenvironment that can promote their growth. Dr Dengler said the team established laboratory models that provided these signals to see what effect it would have on the therapies.
“We found that the Mcl-1 inhibitor alone was less effective when these tumour-promoting signals were present. However, the combination of Mcl-1 inhibitor and ibrutinib, or Mcl-1 inhibitor and venetoclax, was still very effective in killing the cancer cells,” he said.
Testing how new anti-cancer drugs and treatment combinations perform in laboratory models is a crucial step toward clinical trials and eventual approval of new therapies, Dr Dengler said. “Without preclinical evidence, new treatments would not progress to clinical trials in humans.”
Cell death and cancer
Mcl-1 is a member of the Bcl-2 protein family, which controls cell death (apoptosis). Since discovering the critical role of Bcl-2 in cancer development, Institute researchers have dedicated decades to understanding the complex interactions of Bcl-2 family members that determine whether a cell lives or dies.
Professor Adams said Mcl-1 inhibitors were currently in early stage clinical trials for treating several types of cancer, though data from these trials were not yet published.
“Targeting Bcl-2 family members has proven to be a very effective strategy for treating cancers, especially blood cancers,” Professor Adams said.
“For example, venetoclax, which worked well in combination with the Mcl-1 inhibitor in our study, is now an approved cancer therapy for certain types of leukaemia that targets another family member, Bcl-2 itself.
"While our preclinical findings need to be validated further in preclinical and clinical trials, the results certainly look promising for mantle cell lymphoma.”
He said Institute researchers had shown that Mcl-1 played a critical role in maintaining the relentless growth of a number of cancers.
“The utility of Mcl-1 inhibitors could well extend beyond lymphoma and blood cancers, though further testing is required to provide more evidence,” Professor Adams said.
Patient samples were provided by the Metro South Health Cancer Collaborative Biobank, Brisbane. The research was supported by the Australian National Health and Medical Research Council, Cancer Council Victoria, CASS Foundation, Leukaemia Foundation Australia, Leukemia and Lymphoma Society (US), Victorian Cancer Agency and the Victorian Government. All authors are employees of the Walter and Eliza Hall Institute, which receives milestone and royalty payments related to venetoclax. Some study co-authors have received research funding from Servier.
Media enquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
A new compound has been shown to block a protein essential for the growth of many cancers, including melanoma, blood, breast and lung cancers.
Institute researchers have discovered that targeting a cell ‘survival’ protein could help treat some lymphomas, including those that are resistant to existing therapies.
Our researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.
Starting with a landmark discovery in 1988, follow the story of how Institute research has driven development of a breakthrough anti-cancer drug.
This two-part animation from WEHI.TV explains the type of programmed cell death called apoptosis, and how the anti-cancer drug venetoclax works by forcing susceptible cells into this process.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.